Browse by author
Lookup NU author(s): Dr Nishanthi Thalayasingam, Professor Fai NgORCiD
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).
© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology.SS is a chronic, autoimmune condition characterized by lymphocytic infiltration of the exocrine glands and B-cell dysfunction. Current treatment strategies are largely empirical and offer only symptomatic relief for patients. There are no proven treatments that alter disease progression or treat the systemic manifestations of disease. B-cell depletion is used in patients with systemic disease but its overall clinical efficacy has not been demonstrated in two large randomized controlled trials. Studies are now focussing on alternative strategies to target B-cells, including co-stimulation targets, with promising data. It is increasingly clear that clinical trials in SS will require patient stratification and relevant and sensitive outcome measures to identify successful treatment modalities.
Author(s): Thalayasingam N, Baldwin K, Judd C, Ng W-F
Publication type: Article
Publication status: Published
Journal: Rheumatology
Year: 2021
Volume: 60
Issue: Supplement_6
Pages: vi53-vi61
Print publication date: 01/11/2021
Online publication date: 24/12/2021
Acceptance date: 17/05/2021
Date deposited: 30/11/2023
ISSN (print): 1462-0324
ISSN (electronic): 1462-0332
Publisher: Oxford University Press
URL: https://doi.org/10.1093/rheumatology/keab466
DOI: 10.1093/rheumatology/keab466
PubMed id: 34951923
Altmetrics provided by Altmetric
